analysis revealed that OS and CSS were worse in patients with a Gleason score ≥8 and that combined androgen blockade (CAB) treatment provided better OS than non-CAB treatments at any tumor stage. However, OS and CSS were worse in individuals with a prostate-specific antigen >100 ng/ml only in M1b. Conclusions Patient prognosis worsened with stage progression; therefore, current TNM classification system of mPC for PADT was shown to be trustworthy. Each PC cell that develops bone or lymphoid metastasis may exhibit different characteristics.
Introduction
Prostate cancer is one of the most common cancers in males worldwide [1] . Some reports have suggested that prostatespecific antigen (PSA) screening contributes to the detection of early-stage prostate cancer, and hence, the mortality rate from prostate cancer has been decreasing [2] . However, 10-20 % of prostate cancer patients are diagnosed with metastatic disease, even today [3] . Androgen deprivation therapy (ADT) is usually selected as the first-line therapy for metastatic prostate cancer (mPC). Nevertheless, the effectiveness of ADT is generally not permanent, and treatment selection for castration-resistant prostate cancer (CRPC) can be challenging [4] . The effectiveness of docetaxel [5] and other new drugs [6] [7] [8] for CRPC has been reported; however, the improvement in the prognosis of those patients is still not sufficient. The effectiveness of primary ADT (PADT) is thought to have huge impacts on the prognosis of patients with mPC.
Abstract
Purpose The current tumor-node-metastasis (TNM) classification system has been used for many years. The prognosis of patients with metastatic prostate cancer (mPC) treated using primary androgen deprivation therapy (PADT) was analyzed according to the TNM classification. Methods A total of 5618 cases with lymph node metastases only (N1M0), non-regional lymph node metastasis (M1a), bone metastasis (M1b), and distant metastasis (M1c) were selected from the Japanese Study Group of Prostate Cancer database. Overall survival (OS), cancerspecific survival (CSS), and progression-free survival (PFS) rates were calculated using Kaplan-Meier analysis. The influence of clinical variables on patient prognosis was evaluated using the Cox proportional hazard regression model. Results The 5-year OS, CSS, and PFS were 76.0, 83.2, and 38.8 % in N1M0, 57.5, 69.0, and 23.0 % in M1a, 54.0, 63.1, and 23.0 % in M1b, and 40.0, 51.5, and 16.6 % in M1c, respectively. OS, CSS, and PFS worsened as the stages progressed. OS, CSS, and PFS were all significantly worse in N1M1b compared with N0M1b. Multivariate
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The tumor-node-metastasis (TNM) classification system was published by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) and is used for the staging of malignant tumors, including prostate cancer. The staging determined by the TNM classification system is thought to correlate closely with cancer prognosis; therefore, the staging affects the treatment plan. The TNM classification system has been revised several times, and the current edition was the seventh. The TNM classification of mPC has not changed since the fourth edition published in 1992. Regional lymph node metastasis is classified as N1, distant lymph node metastasis is classified as M1a, bone metastasis is classified as M1b, and other sites of distant metastasis are classified as M1c [9] . The most common metastatic sites of PC are the bones, and the frequency of metastases to other sites, including the lymph nodes or viscera, is lower [10, 11] . A recent report showed that the prognosis of metastatic CRPC with visceral metastasis was unfavorable [12] . Although the current TNM classification system has been used for many years, no sufficient evaluation of patient prognosis according to the mPC subcategory classified by the TNM system has been performed to date. In Japan, the Japanese Study Group of Prostate Cancer (J-CaP) study, which was performed to evaluate the therapeutic value of PADT for PC, registered 26,000 cases from 2001 to 2003, and the cases were followed up to the present day. In the current study, mPC cases that had been followed up prospectively for over 10 years were extracted from this cohort and analyzed to evaluate the therapeutic value of PADT according to tumor stage determined using the TNM classification system.
Materials and methods

Patients and background
A total of 26,272 patients who started ADT between 2001 and 2003 were registered at 385 institutions throughout Japan in the J-CaP study [13] . The data collection procedures were approved by the local and central institutional review boards. Of these cases, 5618 N1M0, M1a, M1b, and M1c cases were included in the current study; however, 359 cases of M1x (an unclear M1 subcategory) were excluded. Generally, the registered cases were updated every 3 months with progression data including survival and disease progression. The patients were followed until September 30, 2014. The patients were diagnosed by prostate biopsy at each institution, and the N staging and M staging were determined by the results of imaging findings such as bone scintigraphy, magnetic resonance imaging, and computed tomography. The clinical stage was determined based on the fifth edition of the TNM classification published in 1997 [14] .
PADT was performed using flutamide, chlormadinone acetate (CMA), or diethyl stilbestrol (DES) as anti-androgens (AAs) and 1-or 3-month preparations of goserelin or leuprolide as luteinizing hormone-releasing hormone (LHRH) agonists. LHRH or castration + AA was performed in 3864 patients (69 %), compared with LHRH monotherapy in 519 patients (9 %), castration monotherapy in 288 patients (5 %), LHRH or castration + short AA in 338 patients (6 %), and other treatments in 609 patients (11 %). Short AA was defined as AA therapy given between 30 days before and 60 days after the start of LHRH for flare prevention [15] . LHRH analog or castration + AA was classified as CAB, whereas LHRH or castration monotherapy, LHRH or castration monotherapy + short AA, and other treatments were classified as non-CAB.
Statistical analysis
Patients were followed until death or until they withdrew from the study. Events for PFS were determined by clinicians according to rising PSA levels. PSA failure was determined as a PSA level at least 2.0 ng/ml higher and a 25 % rise from the nadir level, which was confirmed by a second PSA test at least 4 weeks later. The relationships between demographic data were assessed using Chisquared tests. One-way analysis of variance was performed for comparisons of three or more groups with Tukey's HSD post hoc test. Pearson's correlation coefficient was used to determine the relationships between age, PSA, and GS. OS, CSS, and PFS were calculated using the Kaplan-Meier method. Events taken into account to calculate OS and CSS were death for any reason and cancer-related deaths, respectively. The events taken into account for the calculation of PFS were PSA failure, clinical failure, and death. Differences between groups were assessed using log-rank tests. The influences of the clinical variables that affected prognosis were evaluated using Cox proportional hazard regression model. All data analyses were performed using SPSS for Windows (SPSS Inc., Chicago, IL, USA), and p < 0.05 was considered to be statistically significant.
Results
The demographic data available from the database are given in Table 1 . Regarding age, patients with M1b tumors were significantly older than were those in the other groups. PSA levels tended to increase as the stage progressed. The GS was significantly higher in the M1a group compared with the other groups. There was no significant difference in the proportion of patients that received CAB among groups. After a mean follow-up of 3.3 years, 1923 patients (34.2 %) died, of which 1364 (24.3 %) were PC-specific deaths. Figure 1 shows the OS, CSS, and PFS in all groups, as well as the hazard ratios (HRs) analyzed using the Cox hazard model. OS, CSS, and PFS declined as the stage progressed; however, there were no statistically significant differences between M1a and M1b cases. The 5-year OS was 76.0 % in the N1M0, 57.5 % in M1a, 54.0 % in M1b, and 40.0 % in M1c cases (Fig. 1a) . There was no significant difference in CSS between the M1a and M1b groups. The 5-year CSS was 83.2 % in the N1M0, 69.0 % in M1a, 63.1 % in M1b, and 51.5 % in M1c cases (Fig. 1b) . There was no significant difference in the PFS of patients that received PADT between the M1a and M1b groups. The 5-year PFS was 38.8 % in the N1M0, 23.0 % in M1a, 23.0 % in M1b, and 16.6 % in M1c cases (Fig. 1c) .
Among the patients in the M1b group, the 2445 cases of N0M1b and the 1607 cases of N1M1b were compared. The mean age, PSA, and GS were 74.2 years, 651 ng/ml, and 7.6 in the N0M1b group, compared with 72.5 years old, 1325 ng/ml, and 8.0 in N0M1b, respectively; the differences between any of these were considered significant at p < 0.001. The 5-year OS was 58. .7) in the N1M1b; the differences between any of these were considered significant at p < 0.001.
The effects of age, GS, PSA, and the type of ADT on OS and CSS were analyzed using multivariate analysis. The OS of patients aged >75 years was shorter than was that of patients aged ≤75; however, there were no such differences observed in M1a cases. The OS of patients with a GS ≥ 8 was worse than was that of individuals with a GS of ≤7. The OS of patients with a PSA > 100 ng/ml was significantly worse in only patients with M1b disease; however, the OS of patients with a PSA of ≤100 ng/ml was significantly worse in individuals with M1a disease. Conversely, PSA had no effect on the prognosis of patients with N1M0 and M1c disease. The OS of patients treated using CAB was higher than was that of those treated using non-CAB at all stages ( Table 2 ). The CSS of all groups with a GS ≥ 8 was significantly shorter compared with a GS ≤ 7, and CSS was not affected by age in any groups. The CSS after CAB treatment was significantly higher than that after non-CAB treatments in all groups except M1a. The CSS of patients with M1b disease and a PSA ≥ 100 ng/ml was significantly shorter than those with a PSA < 100 ng/ml; however, there was no significant difference in CSS between the N1M0 and M1c groups. In contrast, CSS in patients with M1a disease was worse in those with a PSA ≥ 100 ng/ml than in those with a PSA < 100 ng/ml (Table 3 ). There were no significant correlations between age, PSA, and GS in the N1M0, M1a, and M1c groups. However, there were significant correlations between age and GS (R = −0.58, p < 0.001) and PSA and GS (R = 0.55, p = 0.001) in the M1b group.
Discussion
The current M stage of PC has been determined using the fourth edition of the TNM classification system since 1992 [9] . The effects of treating mPC using PADT, according to subgroups separated by M stage, have not been evaluated in detail. In the current study, the prognosis and factors that influence PADT for mPC in subgroups defined by the current TNM classification were analyzed. The most common metastatic site of PC was the bone in 84 % of the aggregate results from 74,826 PC cases in the USA [10] . In the current study, M1b was the metastatic category of 78 % of cases in the TNM classification, which was likely the result of a high frequency of bone metastasis, consistent with previous reports. The mean patient age was higher in the M1b group compared with the other subcategories, with the peak age of 70-74 years.
The PSA level at diagnosis increased with stage progression. The mean GS was significantly higher in the M1a group than in other groups. OS and CSS deteriorated as the tumor stage progressed; however, there was no significant difference between M1a and M1b. The trends in PFS were the same as those in OS and CSS. As such, the efficacy of PADT was considered to affect the prognosis of the patients. Patients with M1c disease, including visceral metastasis, had the worst prognosis. Previous reports showed that PC patients with extensive metastasis had poor prognosis [16] and that the poor prognosis of CRPC was also reported to be highly affected by liver and lung metastasis, in that order of decreasing influence, regardless of other metastases including bone [12] . In the current study, multivariate analysis revealed that OS was significantly higher in patients treated using CAB compared A B C Fig. 1 The prognosis of metastatic prostate cancer patients treated using primary androgen deprivation therapy. a Overall survival (OS); b cancer-specific survival (CSS); c progression-free survival (PFS). CI confidence interval, HR hazard ratio with than non-CAB, with HRs 0.63-0.75 in all subcategories except M1a. Patients aged >75 years had poor OS in all stages; however, there was no significant difference in CSS between any age groups. Patients with a GS ≥ 8 had significantly worse OS and CSS in all stages. OS and CSS were also significantly worse in patients with M1b disease and a PSA ≥ 100 ng/ml. CSS was also worse in M1a patients with a PSA < 100 ng/ml. However, PSA level had no significant effect on patients with other stage disease. A significant correlation between PSA level and the frequency of bone metastasis was reported previously [17, 18] . In addition, there was no significant correlation between PSA level and the metastatic pattern, except for bone metastasis, in a previous report [11] . Patients with M1a disease subtype and systemic lymph node metastasis had different characteristics from those with M1b disease and bone metastasis, such as higher GS, the absence of correlation between PSA and disease prognosis such as OS or CSS, and a low effect of CAB as the PADT. M1a is categorized as systemic lymph node metastasis, and we did not analyze how many cases with M1b disease had systemic lymph node metastasis in the current study. When patients with N0M1b and N1M1b disease were compared, OS, CSS, and PFS were significantly worse in the N1M1b group compared with N0M1b group, regardless of the higher age in the N1M1b group.
PC is a complex multifaceted and biologically heterogeneous disease [19] ; therefore, each PC cell may have different characteristics, react differently to treatment, and have favorable sites and patterns that support its metastatic proliferation, such as hematogenous or lymphogenous metastasis. The prognosis of patients in the current study became poor as the tumor stage progressed from N1M0 to M1c; however, both the chronological extension and metastatic pattern should be considered to better understand the mPC status of individual patients. The current data did not contain detail regarding the metastatic site; therefore, we did not analyze the prognosis according to the detailed metastatic site. Different patient prognoses depending on the metastatic sites and extension have been reported [12, 16] . The detailed metastatic sites were reported as PUL (pulmonary), OSS (osseous), HEP (hepatic), BRA (brain), LYM (lymph nodes), MAR (bone marrow), PLE (pleura), PER (peritoneum), SKI (skin), and OTH (other) in TNM version 3 [20] . These evaluations were not adopted in the current version of the TNM classification. Nevertheless, these expressions may be convenient for evaluating detailed prognosis according to the metastatic site.
In the current study, the prognosis of in M1 mPC treated using PADT was a mean OS of 6.9 years, a mean CSS of 8.3 years, a mean PFS of 3.5 years; the 3-, 5-, and 10-year survival rates were 68, 53, and 34 %, respectively. Reports from western countries have reported that the 5-and 10-year survival rates of patients with mPC were 23 and 7 %, respectively (SWOG8894; mean age 70.2 years) [21] and that the mean OS of patients with mPC treated using CAB was 2.8-3.0 years [22] . The mean age of J-CaP patients with M1a-c disease was 73.4 years, which was higher than the age of comparable patients in previous reports from western countries. Therefore, Japanese patients with mPC treated using PADT had a better prognosis than did those from western countries. Ethnic differences regarding the effects of ADT have been reported previously [23] , and a large-scale study reported that CSS was higher in Japanese PC patients treated using PADT compared with those in the USA [24] . The present study has some limitations. Because of missing information of some unregistered subcategories such as 359 cases of M1x, not all patients with mPC in the cohort were enrolled. In addition, the treatment and follow-up plans were not unified because the treatment decision-making and follow-up schedules were at the discretion of each hospital and the detailed treatment regimens were not registered. The evaluations of TNM classification were performed using imaging diagnoses; therefore, the staging results may be scattered because of differences in the imaging diagnostic capabilities of each hospital and no central review of the imaging. The GSs in the current study were not reviewed by central pathologist and not influenced by the current ISUP (the International Society of Urological Pathology) classification published in 2005 because the registration period was from 2001 to 2003 [25] . During the follow-up period, novel drugs for PC became available, such as zoledronic acid in 2002 for the management of bone metastasis, which may have improved the prognosis of patients with mPC [26] . Docetaxel, which has improved the prognosis of CRPC, became available in Japan in 2008 [5] . The recently released new drugs for CRPC, such as abiraterone [6] , enzalutamide [7] , and cabazitaxel [8] , were likely to have had little influence on the current study. Patient prognosis may improve as novel treatments are released. The J-CaP database includes a huge number of cases and long-term follow-up from patients that are registered at various hospitals all over Japan. Therefore, the results of the current study are considered to represent the true clinical prognosis of mPC treated using PADT in Japan, regardless of the limitations described above.
Conclusion
In the current study, the prognoses of patients with mPC subcategorized according to the TNM classification system and treated using PADT in the J-CaP database were analyzed. The prognosis worsened as the stage progressed, and therefore, current TNM classification system of mPC for PADT was shown to be trustworthy; however, there were no significant differences in OS, CSS, and PFS between M1a and M1b disease. Each PC cell that develops bone metastasis or lymphoid metastasis may have different characteristics. CAB was more effective for the treatment of mPC than was non-CAB in our database.
Conflict of interest
We declare no conflicts of interest. 
